Back to Search
PHILIP EISENBERG, PH.D.
PH.D.
Clinical Neuropsychologist
NPI: 1689683591Individual
Specialties, Licenses & Credentials
Clinical NeuropsychologistPrimary
Clinical Neuropsychologist
Code: 103G00000X
16639(NY)
Research & Publications (20)
Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial.
PMID 18800218·Eur J Nucl Med Mol Imaging·2009
3-trial
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.
PMID 19273708·J Clin Oncol·2009
3-trial
Development and characterization of an active polyethylene film containing Lactobacillus curvatus CRL705 bacteriocins.
PMID 19680851·Food Addit Contam Part A Chem Anal Control Expo Risk Assess·2008
8-other
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative.
PMID 18398155·J Clin Oncol·2008
8-other
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
PMID 18347007·J Clin Oncol·2008
3-trial
Measuring supportive care in medical oncology practice: lessons learned from the quality oncology practice initiative.
PMID 18688049·J Clin Oncol·2008
6-review
Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.
PMID 17103197·Support Care Cancer·2007
8-other
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
PMID 17031646·Cancer Chemother Pharmacol·2007
3-trial
Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
PMID 16528525·Eur J Nucl Med Mol Imaging·2006
3-trial
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
PMID 16104039·Cancer·2005
3-trial
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
PMID 15837996·J Clin Oncol·2005
3-trial
A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative.
PMID 16087948·J Clin Oncol·2005
8-other
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
PMID 14760130·Ann Oncol·2004
3-trial
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
PMID 14770445·Cancer·2004
3-trial
Reversible changes in adrenocorticotropin (ACTH)-induced adrenocortical steroidogenesis and expression of the peripheral-type benzodiazepine receptor during the ACTH-insensitive period in young rats.
PMID 14962996·Endocrinology·2004
7-preclinical
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
PMID 14692022·Cancer·2004
3-trial
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
PMID 14701778·J Clin Oncol·2004
3-trial
Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis.
PMID 14717976·J Thromb Haemost·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 255 EXECUTIVE DR., SUITE LL107
PLAINVIEW, NY 11803 - Phone
- (631) 455-7258
Quick Facts
- NPI
- 1689683591
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile